Are you weighing the decision to enforce an NDC mandate on ALL Medical Pharmacy Claims? RJ Health’s Analytics team shares the pro’s & con’s of NDC mandates across Pricing, Formulary, and Network Quality Considerations. Here are some practical examples to help illustrate how, at the end-of-the-day, RJ Health believes the answer to the NDC vs. […]
On September 14, 2017, the Food and Drug Administration approved the first biosimilar for Genentech’s Avastin® (bevacizumab), which is the first oncological biosimilar product on the U.S. market. Avastin is approved for eight oncological indications, two of which have an orphan drug exclusivity through 2021. The approval of Amgen’s Mvasi™ (bevacizumab-awwb) includes 6 indications (Table […]
On August 3, 2017 the Food and Drug Administration approved a liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS™, Jazz Pharmaceuticals, Inc.) for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), which are two types of AML having a poor prognosis. VYXEOS is the first agent that […]
Day 2 @ AMCP – A focus on the 340B Program and its Impact on Payors
Gain insight on how your organization can apply modest policy adjustments and some straight-forward network engagement tactics to achieve 6% to 10% in savings on Specialty Drug spend. Take the first step to improving medical drug management controls.
During our discussions with clients we frequently receive questions on exactly what are HCPCS codes and how are they developed. In the coming weeks we will be sharing knowledge and insights on common customer questions. Today we’ll be discussing HCPCS codes. The acronym HCPCS (usually pronounced “hick-pick”) stands for Healthcare Common Procedure Coding System and […]